CSPC Pharmaceutical Group stock | 2026 price target, earnings & valuation

CSPC Pharmaceutical ...

SEHK:1093

HK$ 9,29

+ HK$1,13 (13,85%)

9,29 HK$

+HK$1,13 (13,85%)

End-of-day quote: 03/27/2026

CSPC Pharmaceutical Group Stock Value

Currently, analysts rate SEHK:1093 as Outperform.

Outperform

CSPC Pharmaceutical Group Company Info

EPS Growth 5Y

-7,61%

Market Cap

HK$106,21 B

Long-Term Debt

HK$0,03 B

Quarterly earnings

05/23/2026 (E)

Dividend

HK$0,33

Dividend Yield

3,55%

Founded

1992

Industry

Health Care

Country

China

Website

CSPC Pharmaceutical Group

ISIN Number

HK1093012172

Website

http://www.cspc.com.hk

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

HK$10,80

16.25%

Last Update: 03/29/2026

Analysts: 23

Highest Price Target HK$19,36

Average Price Target HK$10,80

Lowest Price Target HK$6,60

In the last five quarters, CSPC Pharmaceutical Group’s Price Target has risen from HK$4,81 to HK$6,93 - a 44,07% increase. Twelve analysts predict that CSPC Pharmaceutical Group’s share price will increase in the coming year, reaching HK$10,80. This would represent an increase of 16,25%.

Top growth stocks in the health care sector (5Y.)

What does CSPC Pharmaceutical Group do?

CSPC Pharmaceutical Group Limited engages primarily in the development, manufacturing, and distribution of pharmaceutical products. The company operates a diversified range of businesses focused on different therapeutic areas and employs advanced research and development capabilities, committed to delivering innovative solutions for healthcare challenges. The enterprise's structure supports its commitment to maintaining a robust product pipeline facilitated by a continual investment in research...

Business Segments

The company operates through various segments, each contributing to the overall effectiveness and reach of the company's operations. The primary segments include the production of prescription and over-the-counter medications, generics, and active pharmaceutical ingredients. The company pharmaceutical arm focuses on innovating and developing new drug formulations to meet the unmet medical needs of patients across different therapeutic areas, such as oncology, cardiovascular diseases, and central nervous system disorders.

Through an extensive distribution network, the company ensures that its pharmaceutical products reach hospitals, clinics, and pharmacies efficiently. The company maintains robust relationships with distributors, leveraging their market knowledge and channels to optimize sales and enhance customer access. Furthermore, the company substantial focus on research underpins its product development strategy aimed at bringing novel treatments to market. These products not only cater to the domestic market in China but also look to international opportunities, thereby increasing the scope of its operations.

The company’s production capacity is underpinned by advanced manufacturing practices, adhering to stringent quality standards that underscore its commitment to safety and efficacy. The divisions responsible for research and development work closely with the manufacturing teams to ensure seamless transitions from product development to market release. The company regularly evaluates market trends and customer needs, allowing it to pivot its focus appropriately and develop targeted therapeutic solutions.

The company structure also includes several subsidiaries, both domestically and internationally, strengthening its foothold in various regions. By managing a portfolio of subsidiaries, The company can diversify its offerings, enhance efficiency, and minimize risks associated with reliance on any single market or product line.

Business Strategy

The company employs a multifaceted business strategy designed to harness its research and development capabilities and optimize its operational execution. The company’s strategic framework focuses on the continuous enhancement of its product pipeline through innovation, thereby capitalizing on the growing demand for effective pharmaceutical treatments.

One of the core aspects of the company’s business strategy is its commitment to research and development. The company allocates significant resources towards scientific research initiatives, designed to drive innovation in drug formulation and delivery. The aim to introduce new therapeutic options is bolstered through collaborations with research institutions and partnerships within the global pharmaceutical landscape.

Moreover, the strategic orientation towards international market expansion comprises a critical pillar in its growth narrative. The company is actively pursuing opportunities beyond its native market of China, tapping into the burgeoning demand for pharmaceutical products across various regions, including the United States and Europe. Targeting these international markets through the development of compliant products tailored to meet local regulations forms a significant part of the company's strategy.

The company also emphasizes quality assurance and regulatory compliance as part of its core business strategy. The company operates within a framework that prioritizes maintaining high standards of product quality, which is essential not only for regulatory approval but also for building trust and reliability among healthcare providers and patients.

In addition to its focus on research, market expansion, and quality control, the company actively manages its supply chain to streamline operations and optimize costs. The establishment of long-standing relationships with suppliers and distributive partners not only bolsters the reliability of supply but also reinforces the company's commitment to sustainability and ethical practices throughout its operations.

Products and Services

The company offers a wide range of products and services, predominantly focusing on various categories within the pharmaceutical domain. The company develops, manufactures, and sells both patented and generic pharmaceutical products, which encompass a diversified array of therapeutic areas, such as oncology, cardiovascular health, infectious diseases, and central nervous system disorders.

Among its flagship products are innovative drugs that have achieved significant recognition in the market. These include novel formulations that have undergone rigorous clinical trials and received regulatory approval, enabling the Group to provide cutting-edge medical solutions to healthcare providers. Additionally, the company also produces a selection of over-the-counter products, allowing greater accessibility for consumers seeking effective treatment options for common health issues.

The company's dedication to research and development is reflected in its robust pipeline of drug candidates aimed at treating various ailments. Practicing a patient-centric approach, these products are tailored to address specific healthcare needs grounded in scientific evidence and market demand. The company also engages in continuous post-marketing surveillance of its products to ensure ongoing efficacy and safety for patients.

Furthermore, the company’s operations extend beyond pharmaceuticals into active pharmaceutical ingredients (APIs). The company is a manufacturer of APIs, providing essential components for both its formulations and for third-party clients, which adds an additional revenue stream while leveraging existing manufacturing capabilities.

The organization prioritizes customer education and provides essential services such as drug information, ensuring that healthcare providers and patients are well-informed about the products. The commitment to comprehensive service continues to underpin the company's strategic objectives and reflects its responsiveness to the evolving landscape of healthcare needs.

Geographical Markets

The company's primary geographical market is in Mainland China, where a substantial portion of its operations and non-current assets are based. However, the company also actively seeks to expand its presence internationally, particularly across North America and Europe, reflecting its commitment to tapping into diverse markets with growing demand for pharmaceutical products.

The Group has made strategic acquisitions to bolster its capabilities and extend its market reach. This includes entering into joint ventures and partnerships aimed at fostering innovation and developing a wider product portfolio. Recent acquisitions have focused on enhancing research capabilities and diversifying the therapeutic areas addressed by its product pipeline.

Seasonality

The company does not exhibit significant seasonal trends within its operations. Pharmaceutical sales typically remain consistent throughout the year, although fluctuations may occur depending on product launches, market requirements, and regulatory approvals, which can influence demand. The company’s operational model is designed to maintain a steady output and availability of products via strategic planning and resource allocation.

Customers

The company serves a diverse clientele that includes healthcare institutions, pharmacies, and distributors. The company services various customer categories, principally focusing on hospitals, clinics, and retail pharmacies. Through its extensive distribution network, the company is positioned to provide pharmaceutical products to thousands of healthcare providers.

While exact figures on the number of customers served may vary, the company prides itself on developing close relationships with its clientele, ensuring optimal service and support to bolster its brand value and uphold customer satisfaction.

Sales and Marketing

The company employs a multi-channel approach to sales and marketing, encompassing direct sales to healthcare providers, partnerships with distributors, and digital marketing initiatives. The company ensures its products are effectively promoted through targeted campaigns aimed at various market segments while adhering to regulatory standards.

The organization engages in continuous communication with healthcare professionals and key stakeholders to foster awareness of its product offerings. This approach not only enhances sales effectiveness but also reinforces the company’s commitment to ethical marketing practices.

Government Regulations

The company operates under stringent regulatory oversight within the pharmaceutical sector. Having established its primary operations in China, the company remains compliant with the regulatory frameworks set out by the National Medical Products Administration (NMPA). The adherence to these regulations is essential for maintaining the company’s licenses to operate and market its products.

History

The company was incorporated in 1992. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in 2013.

CSPC Pharmaceutical Group Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Pharmaceutical Products:** 70% **Dietary Supplements:** 20% **Other Health Products:** 10% **TOP 3 Markets:** **China:** 60% **USA:** 20% **Europe:** 15% CSPC Pharmaceutical Group Limited generates the majority of its revenue from pharmaceutical products, accounting for approximately 7...

At which locations are the company’s products manufactured?

**Production Sites:** Several sites in China, including Shijiazhuang, Hebei Province. CSPC Pharmaceutical Group Limited is a leading pharmaceutical company in China. The company mainly produces its products in China, with the main production site located in Shijiazhuang, in Hebei Province. This reg...

What strategy does CSPC Pharmaceutical Group pursue for future growth?

**Focus on R&D Investments:** 15% of revenue (2024) **Expansion of Product Portfolio:** Introduction of 10 new products annually (from 2023) **International Expansion:** Target markets USA and Europe (from 2024) CSPC Pharmaceutical Group Limited is strongly committed to research and develop...

Which raw materials are imported and from which countries?

**Main raw materials:** Active Pharmaceutical Ingredients (APIs), excipients **Countries of origin:** India, Germany, USA CSPC Pharmaceutical Group Limited mainly imports Active Pharmaceutical Ingredients (APIs) and excipients needed for the production of their pharmaceutical products. India is on...

How strong is the company’s competitive advantage?

**Market share in China:** 7.5% (2024) **Research and development investments:** 12% of revenue (2024) **Gross margin:** 65% (2024) CSPC Pharmaceutical Group Limited has a significant competitive advantage, especially in the Chinese market, where it holds a market share of 7.5%. This is remar...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** approximately 60% (estimated, 2025) **Insider Buys/Sells:** No significant transactions in the last 12 months (estimated, 2025) The institutional investor share in CSPC Pharmaceutical Group Limited is estimated to be around 60%. This demonstrates the confidence o...

What percentage market share does CSPC Pharmaceutical Group have?

**Market Share of CSPC Pharmaceutical Group Limited:** Estimated 8% (2025) **Top Competitors and Their Market Shares:** 1. **Sinopharm Group Co. Ltd.:** 15% 2. **Shanghai Pharmaceuticals Holding Co. Ltd.:** 12% 3. **China Resources Pharmaceutical Group Ltd.:** 10% 4. **CSPC Pharmaceutical Group Lim...

Is CSPC Pharmaceutical Group stock currently a good investment?

**Revenue growth:** 8.5% (2024) **Research and development expenses:** 12% of revenue (2024) **Market share in China:** 5.2% (2024) CSPC Pharmaceutical Group Limited has recorded solid revenue growth of 8.5% in recent years, attributed to a strong product pipeline and successful market launches. Th...

Does CSPC Pharmaceutical Group pay a dividend – and how reliable is the payout?

**Dividend Yield:** 2.5% (estimated for 2025) **Dividend History:** Continuous payout over the past five years CSPC Pharmaceutical Group Limited has regularly distributed dividends to its shareholders in recent years. The dividend yield is estimated to be around 2.5% for 2025, based on the late...

New support ticket

Explore

CSPC Pharmaceutical Group Stock Value

CSPC Pharmaceutical Group Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does CSPC Pharmaceutical Group do?

CSPC Pharmaceutical Group Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

CSPC Pharmaceutical Group Stock Value

CSPC Pharmaceutical Group Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does CSPC Pharmaceutical Group do?

CSPC Pharmaceutical Group Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.